BackCan-Fite Biopharma Overview

Can-Fite Biopharma Long Term Debt

Latest long-term debt for CANF: $15K.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$15000.00
70.59% YoYΔ $-36000.00 vs prior year quarter

Peer average

Loading

Can-Fite Biopharma Long Term Debt History

Loading

Can-Fite Biopharma vs. peers: Long Term Debt Comparison

Loading

Can-Fite Biopharma Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Can-Fite Biopharma (CANF) FAQ

As of the most recent data (December 2025), CANF shows a long-term debt of $15K. That compares with $51K in the prior-year period — down 70.6% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CANF's long-term debt is now $15K (was $51K) — a 70.6% year-over-year decrease. Pairing that YoY change with peer averages gives a clearer picture of whether Can-Fite Biopharma is outperforming or lagging.

Tracking CANF's long-term debt over time shows whether Can-Fite Biopharma is scaling, shrinking, or reshaping that part of the business. The current reading is $15K That compares with $51K in the prior-year period — down 70.6% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this long-term debt page, Stockcircle has Can-Fite Biopharma's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect long-term debt (currently $15K) with ownership activity and broader fundamentals.

Can-Fite Biopharma's long-term debt is $15K; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.